Sign up to all DiabetesontheNet journals By clicking Subscribe, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters
Essentially, endurance athletes may need to override their dulled thirst mechanism to avoid performance-limiting dehydration
Back in 1965, Samols and his colleagues had helpfully demonstrated that the L-cells reacted with antibodies specific to glucagon which activated the release of insulin (Samols, Marri, Marks, 1965)
PlexusDx compounded GLP-1 ranges $129/mo to $349/mo with no separate consultation fee, generally offering lower entry-point costs for cost-conscious patients
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
The strongest evidence-based case for GLP-1 therapy is in patients who have both overweight or obesity and established cardiovascular disease
